<!DOCTYPE html>

<html lang="en">
<head>
	<meta http-equiv="Content-Type" content="text/html; charset=utf-8">
	<meta name="viewport" content="width=device-width, initial-scale=1">
	<title></title>
	<link rel="stylesheet" href="css/cs.css" type="text/css" />
	<link rel="stylesheet" href="css/animate.css" type="text/css" />
	<script type="text/javascript" src="js/base.js"></script>
	<script type="text/javascript" src="js/Common.js"></script>
    <script type="text/javascript" charset="utf-8">
		

		ANIMATION = [
				
		   ];
		
	</script>

</head>

<body class="slide-3">

<div id="content">
<div class="collage"></div>

<header>CASTLE: Discontinuation rates</header>

<div class="logo"></div>

<section>

<article>

    <div class="chartbk">
     <div>*Lack of efficacy was defined by the investigator and could include reasons such as adverse events and poor adherence, and was not limited<br>only to evidence of increasing HIV RNA.</div>
    
    </div>
    
    <div class="chartdisc">
    <p class="bullet">7 patients (1.6%) in the KALETRA group discontinued due to diarrhea; 3 patients (&lt;1%) in the atazanavir/ritonavir group discontinued due to jaundice.<sup>3</sup></p>
	<p class="bullet">12% of patients in the KALETRA group experienced Grade 2-4 treatment-related diarrhea versus 2% in the atazanavir/ritonavir group.</p>
    <p style="margin-left:17px; text-indent:-6px;">-In patients who switched from KALETRA soft-gel capsules to tablets between weeks 48 and 96 (n=39), the <br>rate of grade 2â€“4 treatment-related diarrhea was 0%, and all-grade diarrhea was reported in 3% (1 patient).<sup>&nbsp;&nbsp;&nbsp;3</sup></p>
    
    </div>
    
</article>
</section>

<div class="buttonwrap">
<button onclick="makecall('PopupWithHeader',Array('cs-03-popup-01','Study Design','<table width=\'830px\'><tr align=\'center\'><td class=\'reference\'>CASTLE Study Design<sup>2,3</sup></td></tr></table>','90','616','10','0','830','500','1','0','1','0'));">Study Design</button>
</div>

<footer>Please click buttons above for Indication and Important Safety Information about KALETRA.</footer>

</div>
</body>
</html>